AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine drinking status
Number of subjects: 964
Study 11299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics associated with healthy diet
Number of subjects: 964
Study 11299089 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics associated with poor diet
Number of subjects: 964
Study 9393379 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine therapy
Number of subjects: 338
Study 9393379 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine therapy
Number of subjects: 338
Study 7649758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help nursing intervention (9-page, 14-step workbook)
Number of subjects: 139
Study 7649758 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 139
Study 7649758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study 3315611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 65
Study 3315611 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 65
Study 31999360 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct questioning
Number of subjects: 125
Study 31999360 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched Count Technique (UCT)
Number of subjects: 125
Study 31999360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lone-actor terrorists
Number of subjects: 125
Study 31999360 — intervention group
Group type: EXPERIMENTAL
Intervention: General population sample
Number of subjects: 125
Study 31587813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile management (MM) group received mobile health care services, including tailored mobile coaching.
Number of subjects: 21
Study 31587813 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM) group received conventional GDM management and could freely use the mobile health care application.
Number of subjects: 21
Study 31587813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile management (MM) group
Number of subjects: 21
Study 31587813 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM) group
Number of subjects: 21
Study 27295716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular fitted dental splint
Number of subjects: 23
Study 27295716 — intervention group
Group type: COMPARATOR
Intervention: Habitual verticalized dental splint
Number of subjects: 23
Study 27295716 — intervention group
Group type: COMPARATOR
Intervention: No splint condition
Number of subjects: 23
Study 26098853 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-Based Breathing Exercise (GBE) for 25 minutes a day, 3 days a week, during a 5 week period
Number of subjects: 38
Study 26098853 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional stroke rehabilitation program)
Number of subjects: 38
Study 24871963 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation for estimating the disposition index (DI) based on metabolic syndrome components.
Number of subjects: 167
Study 24871963 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation based on demographic data and measurements of metabolic syndrome components.
Number of subjects: 167
Study 21224324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 116429
Study 21224324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 116429
Study 21224324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 116429
Study 21224324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 116429
Study 21224324 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 116429
Study 21224324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116429
Study 19413903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent treatment for coronary disease
Number of subjects: 132
Study 17550444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hydroxide
Number of subjects: 46
Study 17550444 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol
Number of subjects: 46
Study 15128052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 372
Study 11461053 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite climbers
Number of subjects: 30
Study 11461053 — intervention group
Group type: COMPARATOR
Intervention: Recreational climbers
Number of subjects: 30
Study 11461053 — intervention group
Group type: COMPARATOR
Intervention: Non-climbers
Number of subjects: 30
Study 9777765 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/d
Number of subjects: 1553
Study 9777765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1553
Study 7886753 — intervention group
Group type: EXPERIMENTAL
Intervention: TALC Direct Recording Scale used by illiterate mothers for growth monitoring
Number of subjects: 0
Study 3587722 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 56
Study 3587722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin Releasing Hormone (TRH)
Number of subjects: 56
Study 30380162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase (AST)
Number of subjects: 452
Study 30380162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hepatitis B virus core antibody (anti-HBc)
Number of subjects: 452
Study 30380162 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 452
Study 30380162 — intervention group
Group type: EXPERIMENTAL
Intervention: AAF index (combined AST, anti-HBc, and LSM)
Number of subjects: 452
Study 30380162 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive models (23 models)
Number of subjects: 452
Study 30380162 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver biopsy avoidance
Number of subjects: 452
Study 29105635 — intervention group
Group type: EXPERIMENTAL
Intervention: Unani medicine Renax
Number of subjects: 50
Study 29105635 — intervention group
Group type: COMPARATOR
Intervention: Allopathic medicine (Spironolactone + Furosemide)
Number of subjects: 50
Study 25559166 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare's nonpayment policy
Number of subjects: 1381
Study 22907732 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 112
Study 22907732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐marker analysis
Number of subjects: 112
Study 21185559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate mouth wash second hourly (Group B)
Number of subjects: 109
Study 21185559 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2% aqueous oral rinse and second hourly irrigations with sterile water (Group C)
Number of subjects: 109
Study 21185559 — intervention group
Group type: COMPARATOR
Intervention: Sterile water oral rinse second hourly (Group A)
Number of subjects: 109
Study 19910812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching followed by 8 front squats + 20% body mass (DSR)
Number of subjects: 20
Study 19910812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 20
Study 19910812 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (SS)
Number of subjects: 20
Study 17304660 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg qd
Number of subjects: 7111
Study 17304660 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg tid
Number of subjects: 7111
Study 15045469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution MR imaging using a microscopy surface coil
Number of subjects: 18
Study 11214952 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (depot leuprolide 3.75 mg)
Number of subjects: 60
Study 11214952 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (5 mg)
Number of subjects: 60
Study 9200359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat intake
Number of subjects: 663
Study 1336675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (3 mg)
Number of subjects: 12
Study 1336675 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 12
Study 1336675 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study 3515922 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 164
Study 3515922 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 164
Study 3515922 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 164
Study 3515922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 31003647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercises
Number of subjects: 107
Study 31003647 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical exercises (Control)
Number of subjects: 107
Study 28111997 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandage (EB)
Number of subjects: 28
Study 28111997 — intervention group
Group type: COMPARATOR
Intervention: Non-standardised tape (NST)
Number of subjects: 28
Study 27588943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L PEG and Ascorbic Acid (Asc)
Number of subjects: 187
Study 27588943 — intervention group
Group type: COMPARATOR
Intervention: 1-L PEG, Ascorbic Acid (Asc) and 20 mg Bisacodyl (Bis)
Number of subjects: 187
Study 24856055 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone vaginal gel 4% (1g/day)
Number of subjects: 60
Study 24856055 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 22414289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 704
Study 22414289 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin monotherapy
Number of subjects: 704
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: UCSD Performance‐Based Skills Assessment (UPSA)
Number of subjects: 463
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief UPSA
Number of subjects: 463
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment battery (NP)
Number of subjects: 463
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: SSPA
Number of subjects: 463
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: UPSA
Number of subjects: 463
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: NP assessment
Number of subjects: 463
Study 20399613 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 463
Study 20399613 — intervention group
Group type: EXPERIMENTAL
Intervention: UPSA and NP
Number of subjects: 463
Study 18175998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 32
Study 18175998 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 32
Study 15616226 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Number of subjects: 22
Study 15616226 — intervention group
Group type: COMPARATOR
Intervention: Ultralente insulin
Number of subjects: 22
Study 12620086 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential currents (IFC)
Number of subjects: 30
Study 12620086 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30
Study 12620086 — intervention group
Group type: COMPARATOR
Intervention: Sham electrotherapy
Number of subjects: 30
Study 10722763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous montelukast (7 mg)
Number of subjects: 51
Study 10722763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg)
Number of subjects: 51
Study 10722763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8623957 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with ondansetron (4 mg IV)
Number of subjects: 90
Study 8623957 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 90
Study 8623957 — intervention group
Group type: COMPARATOR
Intervention: Desflurane only
Number of subjects: 90
Study 8623957 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with ondansetron
Number of subjects: 90
Study 1564466 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily for 4 weeks
Number of subjects: 24
Study 1564466 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative analgesic treatment (diclofenac sodium twice daily for 5-10 days)
Number of subjects: 24
Study 3908111 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 36
Study 3908111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 36
Study 3908111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31203158 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable-polymer Resolute Onyx DES
Number of subjects: 2000
Study 31203158 — intervention group
Group type: COMPARATOR
Intervention: Polymer-free Biosensors BioFreedom DES
Number of subjects: 2000
Study 31203158 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Resolute Onyx and BioFreedom)
Number of subjects: 2000
Study 29733464 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Lacosamide (LCM) 400mg
Number of subjects: 74
Study 29733464 — intervention group
Group type: COMPARATOR
Intervention: IV Fosphenytoin (fPHT) 20mg phenytoin equivalents/kg
Number of subjects: 74
Study 29733464 — intervention group
Group type: COMPARATOR
Intervention: LCM vs fPHT
Number of subjects: 74
Study 29733464 — intervention group
Group type: COMPARATOR
Intervention: LCM and fPHT
Number of subjects: 74
Study 25962813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal steroid injection
Number of subjects: 90
Study 25962813 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injection
Number of subjects: 90
Study 25962813 — intervention group
Group type: COMPARATOR
Intervention: Caudal steroid injection
Number of subjects: 90
Study 23828834 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-induced aphasia therapy (CIAT), 3 hours per day for a total of 30 hours of treatment.
Number of subjects: 100
Study 23828834 — intervention group
Group type: COMPARATOR
Intervention: Conventional aphasia therapy, 3 hours per day for a total of 30 hours of treatment.
Number of subjects: 100
Study 22315331 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg kg(‐1)
Number of subjects: 48
Study 22315331 — intervention group
Group type: EXPERIMENTAL
Intervention: neostigmine 50 μg kg(‐1)/glycopyrrolate 10 μg kg(‐1)
Number of subjects: 48
Study 22315331 — intervention group
Group type: COMPARATOR
Intervention: sugammadex
Number of subjects: 48
Study 22315331 — intervention group
Group type: COMPARATOR
Intervention: neostigmine
Number of subjects: 48
Study 20602109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 36
Study 18043345 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast material with iodine concentration of 370 mg/mL (Group B)
Number of subjects: 80
Study 18043345 — intervention group
Group type: COMPARATOR
Intervention: Contrast material with iodine concentration of 300 mg/mL (Group A)
Number of subjects: 80
Study 16292115 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Parent Psychotherapy (CPP)
Number of subjects: 75
Study 16292115 — intervention group
Group type: COMPARATOR
Intervention: Case management plus treatment as usual
Number of subjects: 75
Study 15332747 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced antenatal care protocols
Number of subjects: 0
Study 15332747 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous maternity care by midwives
Number of subjects: 0
Study 15332747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality reduced protocol by competent midwives
Number of subjects: 0
Study 9137182 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Bankart procedure
Number of subjects: 34
Study 9137182 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic procedure
Number of subjects: 34
Study 7960983 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy to the lungs
Number of subjects: 85
Study 7960983 — intervention group
Group type: COMPARATOR
Intervention: 6 Gy to the lungs
Number of subjects: 85
Study 3235833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (hydrochlorothiazide and triamterene)
Number of subjects: 0
Study 3235833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (hydrochlorothiazide and triamterene) + methyldopa
Number of subjects: 0
Study 3235833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (hydrochlorothiazide and triamterene) + methyldopa (considering all cardiovascular events)
Number of subjects: 0
Study 3235833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2144420 — intervention group
Group type: COMPARATOR
Intervention: Triglycerides (1.68/0.72 g)
Number of subjects: 8
Study 2144420 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fatty acids (1.35/1.065 g)
Number of subjects: 8
Study 2144420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl esters (1.86/1.27 g)
Number of subjects: 8
Study 788738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmefamol, 100 mug and 200 mug
Number of subjects: 0
Study 788738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol, 200 mug
Number of subjects: 0
Study 788738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30963410 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg/day for 8 weeks)
Number of subjects: 36
Study 30963410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29768111 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position for 6 hours
Number of subjects: 60
Study 29768111 — intervention group
Group type: COMPARATOR
Intervention: Supine position for 6 hours
Number of subjects: 60
Study 28290065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 79
Study 28290065 — intervention group
Group type: COMPARATOR
Intervention: Anticipated stress (previous night or morning)
Number of subjects: 79
Study 28290065 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 79
Study 25826644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg (0.04 mL of 25 mg/mL) subconjunctival bevacizumab
Number of subjects: 58
Study 25826644 — intervention group
Group type: COMPARATOR
Intervention: 0.04 mL of balanced salt solution
Number of subjects: 58
Study 23249535 — intervention group
Group type: EXPERIMENTAL
Intervention: True moxibustion at point BL67 plus usual care
Number of subjects: 406
Study 23249535 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion at SP1 (sham moxibustion) plus usual care
Number of subjects: 406
Study 23249535 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 406
Study 21729164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus ALA-PDT
Number of subjects: 80
Study 21729164 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy plus placebo-PDT
Number of subjects: 80
Study 19786776 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 906
Study 19786776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study 16882269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured tubal ectopic pregnancy (REP)
Number of subjects: 130
Study 16882269 — intervention group
Group type: EXPERIMENTAL
Intervention: Unruptured tubal ectopic pregnancy (UREP)
Number of subjects: 130
Study 16882269 — intervention group
Group type: COMPARATOR
Intervention: Normal intrauterine pregnancy (NIUP)
Number of subjects: 130
Study 15197019 — intervention group
Group type: EXPERIMENTAL
Intervention: Care manager offered education, problem-solving treatment, or support for antidepressant management
Number of subjects: 1801
Study 15197019 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study 11258636 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic dysreflexia (ST2)
Number of subjects: 6
Study 11258636 — intervention group
Group type: COMPARATOR
Intervention: No autonomic dysreflexia (ST1)
Number of subjects: 6
Study 9224457 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PMMA IOLs
Number of subjects: 50
Study 9224457 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface‐passivated PMMA IOLs
Number of subjects: 50
Study 9224457 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐surface modified PMMA IOLs
Number of subjects: 50
Study 9224457 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly‐HEMA hydrogel IOLs
Number of subjects: 50
Study 9224457 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 50
Study 8357782 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of quinapril once daily
Number of subjects: 1740
Study 8357782 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 1740
Study 3122717 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (30 mg daily for 1 week)
Number of subjects: 20
Study 3122717 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 31368861 — intervention group
Group type: EXPERIMENTAL
Intervention: ONIRO supplementation
Number of subjects: 70
Study 30030321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement (ONS) intervention
Number of subjects: 7
Study 30030321 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based (FB) intervention
Number of subjects: 7
Study 30030321 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 7
Study 27497359 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus‐eluting stents (BP‐SES)
Number of subjects: 2041
Study 27497359 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer everolimus‐eluting stents (DP‐EES)
Number of subjects: 2041
Study 24771603 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 513